These brief summaries highlight key developments in COPD and how they are likely to affect patient management in the months and years ahead.
AstraZeneca Launches Phase 3 THARROS Trial of Breztri to Reduce Cardiopulmonary Events in COPD
THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
Impact of Regular Exercise on Hospitalization in Patients with COPD: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.
COPD Outcomes: Sedentary Lifestyle Significantly Increases Risk for ED Visits, Hospitalization
Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.
Depression Severity Linked to Higher Odds of Asthma, COPD, and Respiratory Symptoms
The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.